sorafenib has been researched along with nsc 74859 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (nsc 74859) | Trials (nsc 74859) | Recent Studies (post-2010) (nsc 74859) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 101 | 0 | 91 |
| Protein | Taxonomy | sorafenib (IC50) | nsc 74859 (IC50) |
|---|---|---|---|
| Vif | Human immunodeficiency virus 1 | 64.06 | |
| Tat | Human immunodeficiency virus 1 | 75.277 | |
| carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1 | Homo sapiens (human) | 4.636 | |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | 64.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Long, J; Wang, Z; Xiao, W; Zhang, H | 1 |
1 other study(ies) available for sorafenib and nsc 74859
| Article | Year |
|---|---|
The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line; Drug Synergism; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice, Inbred BALB C; Neovascularization, Physiologic; Primary Cell Culture; Receptor, Transforming Growth Factor-beta Type II; Sorafenib; STAT3 Transcription Factor; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2018 |